The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design
Description
Brief Summary
The study will evaluate the incidence of major bleeding (including clinically relevant
non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with
apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous
enoxaparin 40 mg once a day (QD) for 28 days post surgery.
Detailed Description
Apixaban (Eliquis) is an oral anticoagulant for the treatment and prevention of
thromboembolic events. It is advantageous as there is no need to perform routine blood
monitoring tests including, international normalized ratio (INR), partial thromboplastin time
(PTT) and Factor Xa, to determine clotting in participants receiving treatment. Several
studies have shown the efficacy of apixaban for the treatment and prevention of a venous
thromboembolism (VTE).
We anticipate that the same efficacy could be replicated in the prevention of VTE in women
undergoing surgery for gynecologic cancer. An oral-anticoagulant for standard treatment for
prevention of VTE outcomes following surgery could help improve the surgical mortalities
associated with gynecologic oncology surgical patients, improve patient adherence for
outpatient treatment, and reduce VTE surveillance and outcomes.
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
- Suitable candidate for surgery (meets appropriate performance status, no significant cardiac/renal/hepatic dysfunction
- Diagnosis of pelvic malignancy (suspected/confirmed ovarian, endometrial/uterine, cervical cancers, and vulvar cancers) undergoing surgical debulking,
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to surgery,
- Women must not be breastfeeding, WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) apixaban plus 5 half-lives of study drug apixaban (2.5 days) plus 30 days (duration of ovulatory cycle) for a total of 32.5 days post-treatment completion.
- Malignancy or mass that is non-gynecologic in origin (mass/tumor of origin other than reproductive organ such as rectal, abdominal, breast)
- Positive pregnancy test on day of surgery,
- Known history of Venous (Thromboembolism) VTE prior to diagnosis (DVT or Pulmonary Embolism (PE)) due to increased underlying risk of new event
- Concomitant NSAIDS or other anticoagulant/antiplatelet therapy including Acetylsalicylic Acid (Aspirin) (ASA) >81mg/day,
- Selective serotonin re uptake inhibitor (SSRIs) and Serotonin-nor-epinephrine re uptake inhibitor (SNRIs) (common anti-depressant therapies),
- Uncontrolled severe hypertension (systolic >200 mmHg or diastolic >120 mmHg),
- With prosthetic heart valves,
- Active bleeding condition (not limited to: thrombocytopenia, haemophilias, potential bleeding lesions, recent trauma or surgery, recent stroke, confirmed intracranial or intraspinal bleeding),
- Known or documented bleeding disorders not limited to: anti-phospholipid syndrome, homozygotes for Factor V Leiden deficiency, antithrombin III deficiency, protein C deficiency, Protein S deficiency, hyperhomocysteinemia, systemic lupus erythematous, or Prothrombin G2020 gene mutation,
- Significant renal disease as defined by creatinine clearance less than 30 mL/min,
- Significant liver disease as defined as Aspartate Transaminase (AST) or Alanine Transaminase (ALT) twice than normal,
- Concomitant use of dual strong inhibitors or inducers (CYP3A4, P-gp)
- Protein C deficiency (increased risk of skin necrosis do those on injectable anticoagulation),
- Documented allergy to apixaban and/or enoxaparin,
- Patient's deemed otherwise clinically unfit for clinical trial per Investigator's discretion
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI